Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sana Ansari

Urogynecology and Reconstructive Pelvic Surgery Gainesville, GA Medical Doctor

NPI 1629337241 CMS profile 1379539

1315 Jesse Jewell Pkwy Ne Ste 201, Gainesville, GA 30501

Open in the dashboard

General payments

$2,625

36 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sana Ansari of Gainesville, GA is reported in the CMS Open Payments database as having received $2,625 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $837 13
2024 General $1,552 19
2023 General $96 3
2019 General $140 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sana Ansari
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Sana Ansari were reported at $837. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Sana Ansari Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $140 $358 $132–$1,270 $163
2020 $0 $198 $86–$642 $114
2021 $0 $361 $118–$1,182 $132
2022 $0 $410 $128–$1,175 $149
2023 $96 $434 $152–$1,344 $160
2024 $1,552 $494 $193–$1,331 $164
2025 $837 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axonics Modulation Technologies, Inc. $1,311 14 payments
  2. Boston Scientific Corporation $516 7 payments
  3. Medtronic, Inc. $230 4 payments
  4. Coloplast Corp $159 2 payments
  5. Vertex Pharmaceuticals Incorporated $129 2 payments
  6. Tonix Pharmaceuticals, Inc. $84 1 payment
  7. AbbVie, Inc. $62 2 payments
  8. Caldera Medical, Inc $58 1 payment
  9. Escala Medical Inc. $42 1 payment
  10. Ambu Inc. $19 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,664 33 payments
  2. Travel and Lodging $821 2 payments
  3. Education $140 1 payment
Products named General payments · program years 2019–2025
  1. Axonics Urology $1,333 15 payments
  2. Bulkamid $165 2 payments
  3. Axonics Axonics - PNE Lead - URO $152 2 payments
  4. ALTIS $140 1 payment
  5. JOURNAVX $129 2 payments
  6. INTERSTIM $120 3 payments
  7. Solyx SIS System $106 1 payment
  8. Axonics Axonics - Tined Lead - URO $65 1 payment
  9. BOTOX $62 2 payments
  10. Desara $58 1 payment
  11. Other $22 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

91

Median for Obstetrics & Gynecology: 65

Drug cost

$24,383

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

50.5%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 14 $12,431
Gemtesa Vibegron Brand 17 $9,266
Estradiol Generic 30 $1,986
Trimethoprim Generic 15 $586
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 15 $114

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$11,805

Medicare's payments for the services billed

Medicare patients

47

Average age 72

Services billed

192

47 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 53%
Depression 32%
Ischemic heart disease 28%
Diabetes 23%
Chronic kidney disease 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record